Trump signs order to accelerate access to psychedelic drug treatments, directing FDA to fast-track ibogaine and fund federal research

Trump signs an executive order aimed at speeding federal approval pathways for psychedelic drug treatments in the United States. The order directs the FDA to expedite review of ibogaine for medical use, citing claims from U.S. military veteran groups that the drug can help treat post-traumatic stress disorder. Health and Human Services Secretary Robert F. Kennedy Jr. is identified as a key advocate for using drugs like ibogaine for mental health conditions such as depression. At the Oval Office event, Trump also announces $50 million in federal research funding for ibogaine. FDA Commissioner Marty Makary says decisions could come as soon as this summer. The report notes ibogaine is a Schedule I substance, and highlights that Mexico has ibogaine treatment centers that often attract U.S. veterans.